top of page
OBJECTIVE: To investigate a possible linkage between the use of fertility drugs for infertility and the risk of breast and ovarian cancers.
DESIGN: Long-term, historic-prospective study.
SETTING: Fertility clinic in a university hospital.
PATIENT(S): Files of 1,197 infertile women with a mean (+/- SD) follow-up of 17.9+/-5 years (21,407 person-years) were reviewed. Diagnoses, number of courses, and dosage of fertility drugs were extracted from the files.
INTERVENTION(S): Cancers were identified by record linkage to the National Cancer Registry. Histopathologic reports and data on estrogen and progesterone receptors in breast cancer tissue were also reviewed.
MAIN OUTCOME MEASURE(S): Standardized incidence ratio with 95% confidence interval (CI) were used for risk assessment.
RESULT(S): Of 20 breast cancers (standardized incidence ratio, 1.40 [95% CI, 0.83-2.10]), 16 were detected among 780 women who had been exposed to 3,978 cycles of clomiphene citrate (CC) and/or hMG (standardized incidence ratio, 1.65 [95% CI, 0.94-2.68]). The standardized incidence ratio for this cancer was significantly increased only in patients with one or two CC treatments and a dose of
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study.
Potashnik G et al., 1999
Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A
bottom of page